By SPC News Staff
The FDA approved voclosporin (Lupkynis, Aurinia Pharmaceuticals) to be prescribed with a background immunosuppressive regimen to treat adults with active lupus nephritis (LN).
Voclosporin is the first oral therapy indicated for LN, which causes irreversible kidney damage and significantly increases the risk for renal failure, cardiac events and death. It is one of the most serious and common complications of systemic lupus erythematosus (SLE).